Literature DB >> 12860897

Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease.

Sherif F Nagueh1, Judy McFalls, Denise Meyer, Rita Hill, William A Zoghbi, James W Tam, Miguel A Quiñones, Robert Roberts, A J Marian.   

Abstract

BACKGROUND: Systolic (Sa) and diastolic (Ea) myocardial velocities measured by tissue Doppler (TD) imaging (TDI) recently were shown to be decreased in subjects who have mutations causing hypertrophic cardiomyopathy (HCM) but who do not have left ventricular (LV) hypertrophy. By studying these subjects at a later date, we sought to determine whether TDI predicts the subsequent evolution of the HCM phenotype. METHODS AND
RESULTS: Serial 2D and Doppler echocardiography were performed in 12 subjects (age range, 17 to 51 years) with HCM-causing mutations on 2 occasions: before development of hypertrophy and 2 years later. Twelve age- and gender-matched family members without mutations were included as control subjects. In those with mutations, mean septal thickness and LV mass were 1.07+/-0.14 cm and 103.0+/-11 g at baseline, respectively, and increased to 1.30+/-0.36 cm and 193.0+/-78 g at follow-up (P<0.01), with 6 subjects satisfying HCM diagnostic criteria. Sa and Ea velocities in those with mutations were lower compared with control subjects at baseline and follow-up (lateral Sa, 15+/-1.2 versus 8.2+/-2.1 cm/s; lateral Ea, 16.5+/-2.8 versus 8.1+/-2.3 cm/s; P<0.01). At 2 years, left atrial volume and pulmonary venous flow indices of LV filling pressures increased, whereas TD early and late diastolic velocities decreased (all P<0.05) in those with the mutations. Control subjects had no significant interval changes of the above parameters.
CONCLUSIONS: Subsequent development of HCM in subjects with initially reduced TD velocities establishes TDI as a reliable method for early identification of HCM mutation carriers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12860897      PMCID: PMC2908312          DOI: 10.1161/01.CIR.0000084500.72232.8D

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  11 in total

Review 1.  The molecular genetic basis for hypertrophic cardiomyopathy.

Authors:  A J Marian; R Roberts
Journal:  J Mol Cell Cardiol       Date:  2001-04       Impact factor: 5.000

2.  Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy.

Authors:  S F Nagueh; L L Bachinski; D Meyer; R Hill; W A Zoghbi; J W Tam; M A Quiñones; R Roberts; A J Marian
Journal:  Circulation       Date:  2001-07-10       Impact factor: 29.690

3.  Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy.

Authors:  S F Nagueh; H A Kopelen; D S Lim; W A Zoghbi; M A Quiñones; R Roberts; A J Marian
Journal:  Circulation       Date:  2000-09-19       Impact factor: 29.690

4.  Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy.

Authors:  S F Nagueh; N M Lakkis; K J Middleton; W H Spencer; W A Zoghbi; M A Quiñones
Journal:  Circulation       Date:  1999-01-19       Impact factor: 29.690

Review 5.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

6.  Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy.

Authors:  R Patel; S F Nagueh; N Tsybouleva; M Abdellatif; S Lutucuta; H A Kopelen; M A Quinones; W A Zoghbi; M L Entman; R Roberts; A J Marian
Journal:  Circulation       Date:  2001-07-17       Impact factor: 29.690

7.  The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model.

Authors:  Christopher Semsarian; Imran Ahmad; Michael Giewat; Dimitrios Georgakopoulos; Joachim P Schmitt; Bradley K McConnell; Steven Reiken; Ulrike Mende; Andrew R Marks; David A Kass; Christine E Seidman; J G Seidman
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

8.  A transgenic rabbit model for human hypertrophic cardiomyopathy.

Authors:  A J Marian; Y Wu; D S Lim; M McCluggage; K Youker; Q T Yu; R Brugada; F DeMayo; M Quinones; R Roberts
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

9.  Usefulness of Doppler myocardial imaging for identification of mutation carriers of familial hypertrophic cardiomyopathy.

Authors:  Nuno Cardim; Andreas Perrot; Teresa Ferreira; Amadeu Pereira; Karl Joseph Osterziel; Roberto Palma Reis; João Francisco Martins Correia
Journal:  Am J Cardiol       Date:  2002-07-15       Impact factor: 2.778

10.  Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy.

Authors:  Carolyn Y Ho; Nancy K Sweitzer; Barbara McDonough; Barry J Maron; Susan A Casey; J G Seidman; Christine E Seidman; Scott D Solomon
Journal:  Circulation       Date:  2002-06-25       Impact factor: 29.690

View more
  55 in total

Review 1.  Echocardiography: frontier imaging in cardiology.

Authors:  R P Steeds
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

2.  The tale of the three sisters.

Authors:  J Liu; M J Cramer; G E Leenders; J Zhao; P A Doevendans; P G Melman
Journal:  Neth Heart J       Date:  2010-11       Impact factor: 2.380

Review 3.  Hypertrophic cardiomyopathy in childhood.

Authors:  Steven D Colan
Journal:  Heart Fail Clin       Date:  2010-10       Impact factor: 3.179

Review 4.  Hypertrophic cardiomyopathy: from genetics to treatment.

Authors:  Ali J Marian
Journal:  Eur J Clin Invest       Date:  2010-04       Impact factor: 4.686

5.  Exercise-induced left ventricular systolic dysfunction in women heterozygous for dystrophinopathy.

Authors:  Robert M Weiss; Richard E Kerber; Jane K Jones; Carrie M Stephan; Christina J Trout; Paul D Lindower; Kimberly S Staffey; Kevin P Campbell; Katherine D Mathews
Journal:  J Am Soc Echocardiogr       Date:  2010-06-19       Impact factor: 5.251

6.  The Electrocardiogram in Athletes Revisited.

Authors:  George D Katritsis; Demosthenes G Katritsis
Journal:  Arrhythm Electrophysiol Rev       Date:  2013-11-29

7.  Increased periconceptual maternal glycated haemoglobin in diabetic mothers reduces fetal long axis cardiac function.

Authors:  H M Gardiner; L Pasquini; J Wolfenden; E Kulinskaya; W Li; M Henein
Journal:  Heart       Date:  2005-11-08       Impact factor: 5.994

8.  Structural abnormalities of the left ventricle in hypertrophic cardiomyopathy mutation carriers detectable before the development of hypertrophy.

Authors:  T Germans; A A M Wilde; C J A van Echteld; O Kamp; Y M Pinto; A C van Rossum
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

9.  Beyond the measurement of QRS complex toward mechanical dyssynchrony: cardiac resynchronisation therapy in heart failure patients with a normal QRS duration.

Authors:  A Auricchio; C M Yu
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

Review 10.  A clinical approach to inherited hypertrophy: the use of family history in diagnosis, risk assessment, and management.

Authors:  Kyla E Dunn; Colleen Caleshu; Allison L Cirino; Carolyn Y Ho; Euan A Ashley
Journal:  Circ Cardiovasc Genet       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.